Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung

International Journal of Biological Markers

Volumn 18, Issue 3, 2003, Pages 188-194

  Ruibal, Alvaro ^a   Nunez M I ^a   Rodriguez J ^b   Jimenez L ^c   Del Rio, M C ^d   Zapatero, J ^c  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Jimenez Diaz Foundation   (Spain)

^d UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

Author keywords

Cytosol; Neuron specific enolase (NSE); Squamous cell lung carcinoma

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CD44V5 ANTIGEN; CD44V6 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; HERMES ANTIGEN; HYALURONIC ACID; LYMPHOCYTE ANTIGEN; NEURON SPECIFIC ENOLASE; ONCOPROTEIN; PROTEIN PS2; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL PARAMETERS; ANEUPLOIDY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL CYCLE S PHASE; CELL NUCLEUS; CELL SURFACE; CORRELATION ANALYSIS; CYTOSOL; DIPLOIDY; DISEASE ASSOCIATION; DRUG RESPONSE; ENZYME ANALYSIS; FEMALE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PLOIDY; PROTEIN ANALYSIS; PROTEIN CONTENT; STATISTICAL ANALYSIS;

EID: 0141920758     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4681     Document Type: Article

References (42)

1. Marangos PJ, Zis AP, Clark RI, et al. Neuronal and non-neuronal and hybrid form of enolases in brains: Structural, immunological and functional comparison. Brain Res 1978; 150: 117-33.
2. Haimoto M, Takahadshi Y, Kohikawa T, Nagura H, Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985; 52: 257-63.
3. Addis BJ, Hamid Q, Ibrahim NB, Fahey M, Bloom SR, Polak JM. Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung. J Pathol 1987; 153: 137-50.
4. Bonner JA, Sloan JA, Rowland KM, et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 2000; 6: 597-601.
5. Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: An early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998; 82: 1049-55.
6. Buamah PK, Drake SR, Smedley HM, Bodger WA, Skillen AW. Neuron-specific enolase during chemotherapy of small cell lung cancer. J Surg Oncol 1990; 44: 1-4.
7. Kyrkou KA, Iatridis SG, Athanassiadou PP, Lambropoulou S, Liossi A. Immunodetection of neuron-specific enolase and keratin in cytological preparations as an aid in the differential diagnosis of lung cancer. Diagn Cytopathol 1986; 2: 217-20.
8. Tanaka M, Inase N, Miyake S, Yoshizawa Y. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anticancer Res 2001; 21: 291-4.
9. Johansson L, Andersson C, Albin M. Immunohistochemical study of 158 lung carcinomas. APMIS 1992; 100: 914-21.
10. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988; 90: 641-52.
11. Diez M, Torres A, Ortega L, et al. Value of serum neuron-specific enolase in non small cell lung cancer. Oncology 1993; 50: 127-31.
12. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21.1, neuron-specific enolase and prognosis of small-cell lung cancer: Prospective study in 621 patients. Lung Cancer 2001; 31: 221-31.
13. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48: 1931-7.
14. Diez M, Torres A, Ortega L, et al. Value of serum neuron-specific enolase in non-small cell lung cancer. Oncology 1993; 50: 127-31.
15. Vinolas N, Molina R, Galan MC, et al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: Preliminary report. Anticancer Res 1998; 18: 631-4.
16. Ariyoshi Y, Kato K, Ueda R, et al. Biological and clinical implication of neuron specific enolase and creatine kinase BB in small cell lung cancer. Jpn J Clin Oncol 1986; 16: 213-21.
17. O'Shea P, Casidy M, Freaney R, McCarthy P, Fennelly J. Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer. Int J Med Sci 1995; 164: 31-6.
18. Van Zandwijk N, Jassem E, Bonfrer JM, Mooi WJ, Van Tinteren H: Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992; 19 (1 Suppl 2): 37-43.
19. Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumor marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41: 311-20.
20. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10: 209-19.
21. Linnoila RJ, Ruckdeschel JC, Piantadosi S, Jensen SM, Mulshine JL. The impact of neuroendocrine and epithelial differentiation on recurrence and survival in patients with resected non-small cell lung cancer: The LCSG experience. Proc Am Soc Clin Oncol 1991; 10: 28 (abstract).
22. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH: Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991; 2: 355-60.
23. Ruibal A, Nuñez MI, Pardo C, Rodriguez J. Cytosolic neuron specific enolase levels in lung adenocarcinomas. Oncología 2002; 25: 432-3.
24. Ruibal A, Núñez MI, Del Rio MC, García S, Rodríguez J, Alvarez De Linera JF. Cytosolic cathepsin D levels in squamous carcinomas of the lung. Med Clin (Barc) 2003; 120: 81-4.
25. Pelletier MP, Edwards MD, Michel RP, Halwani F, Morin JE. Prognostic markers in resectable non-small cell lung cancer: A multivariate analysis. Can J Surg 2001; 44: 180-8.
26. Uchiyama B, Saijo Y, Kumano N, et al. Expression of nucleolar protein p120 in human lung cancer: Difference in histological types as a marker for proliferation. Clin Cancer Res 1997; 3: 1873-7.
27. Sikora J, Dworacki G, Trybus M, Batura-Gabryel H, Zeromski J. Correlation between DNA content, expression of Ki67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions. Tumor Biol 1998; 19: 196-204.
28. Ishikuro A, Dosaka-Akita H, Kato M, et al. Ki-67 labeling indices in non-small cell lung cancer: Comparison between image cytometry and flow cytometry. Cytometry 1997; 39: 186-91.
29. Nguyen VN, Mirejovsky P, Mirejovski T, Melinova L, Mandys V: Expression of cyclin D1, Ki67 and PCNA in non-small cell lung cancer: Prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000; 102: 323-38.
30. Visakorpi T, Holli K, Hakama M. High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma. Acta Oncol 1995; 34: 605-9.
31. Filderman AE, Silvestrini GA, Gatsonis C, Luthringer DJ, Honig J, Flynn SD. Prognostic significance of tumor proliferative fraction and DNA content in stage I non small cell lung cancer. Am Rev Respir Dis 1992; 146: 707-10.
32. Kawai T, Suzuki M, Kono S, et al. Proliferating cell nuclear antigen and Ki67 in lung carcinoma. Correlation with DNA flow cytometric analysis. Cancer 1994; 74: 2468-75.
33. Alvarez Riesgo JA, Sampedro A, Fernandez R, Folgueras MV, Salas-Bustamante A, Cueto A. Cell proliferation activity and prognostic index in squamous cell lung carcinoma. Anal Cell Pathol 1998; 16: 233-42.
34. Kolodziejski L, Niezabitowski A, Gasinska A. Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer. Lung Cancer 1997; 16: 173-82.
35. Jeanfaivre T, Chassevent A, Geslin J, Larra F, Tuchais E. Prognostic value of flow cytometry in squamous cell bronchogenic cancer. A retrospective study of 61 cases. Bull Cancer 1997; 84: 597-602.
36. Yamaguchi K, Okami K, Hibi K, Wehage SL, Jen J, Sidransky D. Mutation analysis of hBUN1 in aneuploid HNSCC and lung cancer lines. Cancer Lett 1999; 139: 183-7.
37. Rice TW, Bauer TW, Gephardt GN, Medendorp SV, McLain DA, Kirby TJ. Prognostic significance of flow cytometry in non-small cell lung cancer. J Thorac Cardiovasc Surg 1993; 106: 210-7.
38. Kasprzyk M, Dyszkiewicz W, Wiktorowicz K, Piwkowski C, Gasiorowski L. Prognostic significance of DNA analysis in neoplastic cells of patients with squamous cell lung neoplasms treated surgically. Pneumonol Alergol Pol 1999; 67: 103-10.
39. Jeanfaivre T, Chassevent A, Larra F, Tuchais E. Contribution of flow cytometry in the prognostic evaluation of non-small cell lung cancers. Review of the literature. Bull Cancer 1994; 81: 605-9.
40. Vom M, Kayser K, Mettern J. Demonstration of independent cellular prognostic factors in squamous carcinoma of the lung. Strahlenther Onkol 1989; 165: 587-92.
41. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small cell lung cancer? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg 1993; 106: 90-4.
42. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995; 110: 601-5.